On Feb 04, 2026, ABBV reported earnings of 2.71 USD per share (EPS) for Q4 25, beating the estimate of 2.70 USD, resulting in a 0.17% surprise. Revenue reached 16.62 billion, compared to an expected 16.75 billion, with a -0.78% difference. The market reacted with a -3.79% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 15 analysts forecast an EPS of 3.19 USD, with revenue projected to reach 15.28 billion USD, implying an increase of 17.71% EPS, and decrease of -8.07% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eli Lilly & Co.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$6.73
Actual
$7.54
Surprise
+11.92%
Novartis AG
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.02
Actual
$2.02
Surprise
+0.27%
Merck & Co., Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$2.02
Actual
$2.04
Surprise
+0.52%
Novo-Nordisk A/S
Report Date
Feb 04, 2026 For Q4 25
Estimate
$5.97
Actual
$6.32
Surprise
+5.77%
Pfizer Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$0.57
Actual
$0.66
Surprise
+14.29%
Sanofi - ADR
Report Date
Jan 29, 2026 For Q4 25
Estimate
$1.46
Actual
$1.53
Surprise
+4.22%
FAQ
What were ABBVIE INC.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, ABBVIE INC. reported EPS of $2.71, missing estimates by 0.17%, and revenue of $16.62B, -0.78% below expectations.
How did the market react to ABBVIE INC.'s Q4 2025 earnings?
The stock price moved down -3.79%, changed from $225.66 before the earnings release to $217.11 the day after.
When is ABBVIE INC. expected to report next?
The next earning report is scheduled for Apr 23, 2026.
What are the forecasts for ABBVIE INC.'s next earnings report?
Based on 15
analysts, ABBVIE INC. is expected to report EPS of $3.19 and revenue of $15.28B for Q1 2026.